We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

122 hedge funds and large institutions have $993M invested in Crinetics Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more call options, than puts

Call options by funds: $43K | Put options by funds: $20K

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

5.79% more ownership

Funds ownership: 96.05% → 101.83% (+5.8%)

5% more capital invested

Capital invested by funds: $948M → $993M (+$45.1M)

0% more funds holding

Funds holding: 122 → 122 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

Holders
122
Holders Change
–
Holders Change %
0%
% of All Funds
1.96%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
13
Increased
45
Reduced
37
Closed
13
Calls
$43K
Puts
$20K
Net Calls
+$23K
Net Calls Change
-$2.48M

Top Buyers

Rank Fund Capital Flow
1
FC
Finepoint Capital
Massachusetts
+$14.5M
2
PBA
Paradigm Biocapital Advisors
New York
+$6.53M
3
Millennium Management
Millennium Management
New York
+$4.47M
4
State Street
State Street
Massachusetts
+$3.46M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$3.14M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$22.6M
2
BI
BVF Inc
California
-$16.6M
3
BBA
Baker Bros. Advisors
New York
-$14.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$14.1M
5
N
Nuveen
North Carolina
-$2.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$10.5M +$4.47M +253,736 +79%
Northern Trust
27
Northern Trust
Illinois
$8.8M +$42.6K +2,418 +0.5%
Janus Henderson Group
28
Janus Henderson Group
United Kingdom
$7.43M +$468K +26,568 +7%
Walleye Capital
29
Walleye Capital
New York
$7.42M +$2.74M +155,545 +62%
MB
30
MPM BioImpact
Massachusetts
$6.8M +$122K +6,929 +2%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$6.44M +$181K +10,277 +3%
Charles Schwab
32
Charles Schwab
California
$6.28M +$121K +6,865 +2%
Ensign Peak Advisors
33
Ensign Peak Advisors
Utah
$4.95M +$3.14M +177,945 +193%
SCM
34
Silverarc Capital Management
Massachusetts
$2.8M +$65.6K +3,720 +2%
Morgan Stanley
35
Morgan Stanley
New York
$2.79M +$891K +50,556 +50%
First Manhattan
36
First Manhattan
New York
$2.79M – – –
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$2.74M – – –
NLVP
38
New Leaf Venture Partners
New York
$2.58M – – –
N
39
Nuveen
North Carolina
$2.52M -$2.8M -158,898 -54%
Goldman Sachs
40
Goldman Sachs
New York
$2.44M +$188K +10,648 +9%
MPAM
41
Monarch Partners Asset Management
Massachusetts
$2.36M -$33.2K -1,886 -1%
Bank of America
42
Bank of America
North Carolina
$2.27M +$1.14M +64,610 +109%
Rafferty Asset Management
43
Rafferty Asset Management
New York
$1.95M +$547K +31,045 +41%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$1.82M -$513K -29,100 -23%
HS
45
HighVista Strategies
Massachusetts
$1.72M +$32.5K +1,846 +2%
Swiss National Bank
46
Swiss National Bank
Switzerland
$1.66M +$49.3K +2,800 +3%
AI
47
Atom Investors
Texas
$1.49M +$573K +32,541 +67%
UBS Group
48
UBS Group
Switzerland
$1.48M +$1.28M +72,555 +891%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$1.45M -$123 -7 -0%
Fisher Asset Management
50
Fisher Asset Management
Washington
$1.41M +$415K +23,568 +44%
1
2
3 4 5

CRNX Hedge Fund Activity: Q4 2022 in Review

122 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2022, worth a combined $993M — up 4.8% from $948M a quarter earlier.

Fund positioning in CRNX was balanced in Q4 2022: 13 funds opened new positions, 13 closed out, 45 added to existing stakes and 37 trimmed.

The largest buyer was Finepoint Capital, opening a new position worth an estimated $14.5M. The largest seller was Perceptive Advisors, cutting an estimated $22.6M.

  • 122 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $993M of Crinetics Pharmaceuticals stock for Q4 2022, up 4.8% quarter-over-quarter.
  • 13 funds opened new Crinetics Pharmaceuticals positions in Q4 2022 and 13 closed out, a net change of 0 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2022 was Finepoint Capital, an estimated $14.5M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2022 was Perceptive Advisors, an estimated $22.6M sold.

Based on aggregated 13F filings for Q4 2022.